Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, cilt.23, sa.3, 2025 (ESCI)
Introduction We aimed to investigate the effects of clinical and laboratory characteristics before neoadjuvant chemotherapy (NAC) on prognosis and the relationship between the number of NAC cycles and overall survival (OS) and disease-free survival (DFS) in patients with advanced ovarian cancer. Methods The records of 135 patients with epithelial ovarian cancer (EOC) who were not suitable for surgery at the time of diagnosis and who received neoadjuvant treatment were retrospectively analyzed. The Kaplan-Meier method and log-rank test were used for survival analyses. In all analyses, p value < 0.05 was considered statistically significant. Results Estrogen receptor (ER)-negative patients had shorter survival times compared to ER-positive patients. Patients with paraaortic lymph node involvement had shorter survival (*P < 0.05). As NLR (neutrophil/lymphocyte ratio) increased, survival time was found to shorten (*P < 0.05). Patients who received three or fewer courses of neoadjuvant chemotherapy had a median survival time (mOS) of 60 months, while patients who received more than three courses had a mOS of 40 months. While a numerical difference was observed between both groups in terms of survival time, no statistically significant difference was found (*P = 0.05). Although there was a numerical difference in DFS between the two groups, there was no statistically significant difference (P = 0.651). Conclusions In our study, ECOG performance status, estrogen receptor status, NLR and paraaortic lymph node involvement were found to be associated with OS in patients with advanced EOC who underwent interval debulking after neoadjuvant treatment. No significant correlation was found between the number of NACs and OS and DFS.